[Chronic heart failure and atrial fibrilation: aspects of management].
Tereshchenko
S N
SN
Bulanova
N A
NA
Kositsyna
I V
IV
Morozova
M N
MN
Uteshev
Iu A
IuA
D000208:Acute Disease; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000638:Amiodarone / Q000008:administration & dosage / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D017298:Bisoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004077:Digoxin / Q000008:administration & dosage / Q000627:therapeutic use; D004554:Electric Countershock; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D011802:Quinidine / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013015:Sotalol / Q000008:administration & dosage / Q000627:therapeutic use; D013565:Sympatholytics / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents; D013565:Sympatholytics; D014665:Vasodilator Agents; D004077:Digoxin; D013015:Sotalol; D011802:Quinidine; D000638:Amiodarone; D017298:Bisoprolol